- 期刊
Lercanidipine and Losartan Effects on Blood Pressure and Fibrinolytic Parameters
Lercanidipine與Losartan對降血壓及血栓溶解因子的影響
摘要
降血壓藥物除了可降低血壓外也可能影響血栓溶解。我們進行一隨機分配的研究來探討lercanidipine及losartan對血壓及血栓溶解因子（胞漿素原活化抑制因子－1,D雙體與纖維原）的影響。所有的病人皆為原發性高血壓患者且接受2週安慰劑後隨機分給每天lercanidipine 10-20 mg或losartan 50-100 mg的治療。總共有26位病人完成本研究。在8周的治療後兩群病人皆顯著降低收縮壓(SBP)與舒張壓(DBP) （SBP，P=0.034 & 0.050；DBP，p=0.018 & 0.034，分別對lercanidipine與losartan）。兩種降血壓藥物都有良好的耐受性。只有在接受lercanidipine治療的病人胞漿素原活化抑制因子－1濃度明顯下降(57.1±4.7 to 43.1±4.8 ng/mL, P=0.047)。D雙體與纖維原在兩群病人都無顯著變化。本研究顯示lercanidipine及losartan治療台灣原發性高血壓患者是有效且有好的耐受性。Lercanidipine治療可能提供額外血栓溶解的好處。
並列摘要
Antihypertensive agents may modulate fibrinolysis in addition to reducing blood pressure. We conducted a randomized trial to assess the effects of lercanidipine and losartan on blood pressure (BP) lowering and three fibrinolytic parameters: plasminogen activator inhibitor-1 (PAI-1), D-dimer, and fibrinogen. All patients enrolled had essential hypertension and underwent a placebo run-in period of 2 weeks before randomization to either lercanidipine tablets 10-20 mg once daily or losartan tablets 50-100 mg once daily. Twenty-six patients completed this study. After 8 weeks of treatment, both groups of patients had significantly reduced systolic (SBP) and diastolic BP (DBP) (SBP, p=0.034 and 0.050, respectively; DBP, p=0.018 and 0.034 for lercanidipine and losartan, respectively). Both drugs were well tolerated. Only in the group treated with lercanidipine was PAI-1 concentration significantly reduced (57.1±4.7 to 43.1±4.8 ng/mL, p=0.047). No difference was found with D-dimer and fibrinogen in either group. This study shows that both lercanidipine and losartan are effective antihypertensive drugs in patients with essential hypertension. Lercanidipine may provide additional benefit in fibrinolysis.